Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Retosiban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR known ✓ | P30559 | 20/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Retosiban SCHEMBL20240377 | 1.00 | OXTR (1.00) | OXTRAVPR2 | |
| Retosiban SCHEMBL5224662 | 1.00 | OXTR (1.00) | OXTRAVPR2 | |
| Retosiban SCHEMBL29376892 | 1.00 | OXTR (1.00) | OXTRAVPR2 | |
| Retosiban SCHEMBL21255735 | 1.00 | OXTR (1.00) | OXTRAVPR2 | |
| SCHEMBL5165906 | 0.93 | OXTR (0.87) | OXTRAVPR2 | |
| SCHEMBL5166368 | 0.93 | OXTR (0.87) | OXTRAVPR2 | |
| SCHEMBL14440654 | 0.88 | OXTR (0.79) | OXTRAVPR2 | |
| SCHEMBL233458 | 0.88 | OXTR (0.79) | OXTRAVPR2 | |
| SCHEMBL232783 | 0.88 | OXTR (0.79) | OXTRAVPR2 | |
| SCHEMBL30317770 | 0.88 | OXTR (0.78) | OXTRAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183029-B2 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | FERRING B.V. (NL) | 2019-01-22 | — | — | US | claimed |
| US-20180161338-A1 | RETOSIBAN FOR THE TREATMENT OF PRE-TERM LABOUR | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | US | claimed |
| US-20170189415-A1 | OXYTOCIN RECEPTOR ANTAGONIST THERAPY IN THE LUTEAL PHASE FOR IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES | FERRING B.V. (NL) | 2017-07-06 | — | — | US | claimed |
| US-20170119779-A1 | RETOSIBAN FOR THE TREATMENT OF PRE-TERM LABOUR | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-05-04 | — | — | US | claimed |
| EP-3154548-A1 | RETOSIBAN FOR THE TREATMENT OF PRE-TERM LABOUR | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-04-19 | — | — | EP | claimed |
| US-9452169-B2 | Substituted diketopiperazines and their use as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2016-09-27 | — | — | US | claimed |
| US-20160074413-A1 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2016-03-17 | — | — | US | claimed |
| WO-2015192878-A1 | RETOSIBAN FOR THE TREATMENT OF PRE-TERM LABOUR | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-23 | — | — | WO | claimed |
| US-20150105387-A1 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LTD (GB) | 2015-04-16 | — | — | US | claimed |
| US-8357685-B2 | Substituted diketopiperazines and their use as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2013-01-22 | — | — | US | claimed |
| US-20120004229-A1 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-01-05 | — | — | US | claimed |
| US-8071594-B2 | Substituted diketopiperazines and their use as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | claimed |
| US-20070149524-A1 | Substituted diketopiperazines and their use as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | claimed |
| EP-1641787-B1 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCYN ANTAGONISTS | GLAXO GROUP LTD (GB) | 2007-05-02 | — | — | EP | claimed |
| EP-1641787-A1 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCYN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-04-05 | — | — | EP | claimed |
| WO-2005000840-A1 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-01-06 | — | — | WO | claimed |
| EP-3501533-B1 | OBE001 FOR USE IN THE TREATMENT IN IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES | FERRING BV (NL) | 2025-07-09 | — | — | EP | disclosed |
| US-20230355568-A1 | THERAPEUTIC AGENT FOR MALIGNANT MESOTHELIOMA AND METHOD FOR SELECTING PATIENT HAVING MALIGNANT MESOTHELIOMA | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20070149524-A1 | Substituted diketopiperazines and their use as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| EP-1641787-B1 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCYN ANTAGONISTS | GLAXO GROUP LTD (GB) | 2007-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004229-A1 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS | OXTR, AVPR2, AVPR1B | OXTR 1/4885AVPR2 2/4885 |
| US-20150105387-A1 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS | OXTR, AVPR2, AVPR1B | OXTR 1/4885AVPR2 2/4885 |
| US-20160074413-A1 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS | OXTR, AVPR2, AVPR1B | OXTR 1/4885AVPR2 2/4885 |
| US-20070149524-A1 | Substituted diketopiperazines and their use as oxytocin antagonists | OXTR, AVPR2, MC2R | OXTR 1/4885AVPR2 2/4885 |
| US-10183029-B2 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | OXTR, GNRHR, LHCGR | OXTR 1/4885AVPR2 8/4885 |
| US-20230355568-A1 | THERAPEUTIC AGENT FOR MALIGNANT MESOTHELIOMA AND METHOD FOR SELECTING PATIENT HAVING MALIGNANT MESOTHELIOMA | OXTR, MST1R, OGFR | OXTR 1/4885AVPR2 38/4885 |
| US-20170189415-A1 | OXYTOCIN RECEPTOR ANTAGONIST THERAPY IN THE LUTEAL PHASE FOR IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES | OXTR, GNRHR, LHCGR | OXTR 1/4885AVPR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.